Show simple item record

dc.contributor.authorHajiev, Saur
dc.contributor.authorAllara, Elias
dc.contributor.authorMotedayеn Aval, Leila
dc.contributor.authorArizumi, Tadaaki
dc.contributor.authorBettinger, Dominik
dc.contributor.authorPirisi, Mario
dc.contributor.authorRimassa, Lorenza
dc.contributor.authorPressiani, Tiziana
dc.contributor.authorPersoneni, Nicola
dc.contributor.authorGiordano, Laura
dc.contributor.authorKudo, Masatoshi
dc.contributor.authorThimme, Robert
dc.contributor.authorPark, Joong-Won
dc.contributor.authorTaddei, Tamar H
dc.contributor.authorKaplan, David E
dc.contributor.authorRamaswami, Ramya
dc.contributor.authorPinato, David J
dc.contributor.authorSharma, Rohini
dc.date.accessioned2021-10-19T15:43:22Z
dc.date.available2021-10-19T15:43:22Z
dc.date.issued2021-01
dc.date.submitted2020-05-06
dc.identifier.issn0007-0920
dc.identifier.others41416-020-01116-9
dc.identifier.other1116
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/329620
dc.description.abstractBACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly. METHODS: In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models. RESULTS: Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93-1.08), p = 0.97). There was no relationship between starting dose of sorafenib 800 mg vs 400 mg/200 mg and OS between those <75 and ≥75 years. The elderly experienced a similar overall incidence of grade 2-4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%, p = 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary between different starting doses of sorafenib. CONCLUSIONS: Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectArticle
dc.subject/692/699/67/1059/602
dc.subject/692/4028/67/1504/1610/4029
dc.subjectarticle
dc.titleImpact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
dc.typeArticle
dc.date.updated2021-10-19T15:43:22Z
prism.endingPage413
prism.issueIdentifier2
prism.publicationNameBr J Cancer
prism.startingPage407
prism.volume124
dc.identifier.doi10.17863/CAM.77069
dcterms.dateAccepted2020-09-25
rioxxterms.versionofrecord10.1038/s41416-020-01116-9
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidAllara, Elias [0000-0002-1634-8330]
dc.contributor.orcidSharma, Rohini [0000-0003-2441-549X]
dc.identifier.eissn1532-1827
cam.issuedOnline2020-10-19


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record